NCT04940299 2026-03-06Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaM.D. Anderson Cancer CenterPhase 2 Active not recruiting35 enrolled
NCT02812420 2026-03-05Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before SurgeryM.D. Anderson Cancer CenterPhase EARLY_PHASE1 Active not recruiting54 enrolled
NCT03582475 2025-11-12Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or ProstateJonsson Comprehensive Cancer CenterPhase 1 Active not recruiting15 enrolled 17 charts
NCT00479128 2025-10-28Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid TumorsM.D. Anderson Cancer CenterPhase 1 Active not recruiting80 enrolled
NCT00082706 2025-09-09Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal RemnantM.D. Anderson Cancer CenterPhase 2 Active not recruiting46 enrolled
NCT06638931 2025-05-28ANTARESInstituto do Cancer do Estado de São PauloPhase 2 Active not recruiting28 enrolled